Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid

Ali, S.; Kelly, Charles; Challacombe, S. J.; Donaldson, Ana Nora; Dart, John K.G.; Gleeson, Mike; Setterfield, Jane

doi:10.1111/bjd.14351

Cited by 31 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the secretory component was not determined in this investigation. In contrast, SIgA antibodies have been found in parotid saliva from patients with MMP . Further investigations are being carried out in this area.…”

Section: Discussionmentioning

confidence: 94%

“…Salivary biomarkers are currently being used in oral and breast cancer diagnostics with much potential . Furthermore, we have previously demonstrated the presence of salivary antibodies IgG and IgA to BP180‐NC16a in patients with mucous membrane pemphigoid (MMP) . In this study, we investigated the presence of salivary and serum anti‐Dsg3 antibodies in sequential samples from patients with PV.…”

mentioning

confidence: 98%

See 1 more Smart Citation

Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

mentioning

confidence: 98%

Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…With a BP180 NC16A ELISA, reactivity was seen in 45% of MMP patients' saliva compared with 52% in serum. In 64 MMP patients, additional use of saliva increased detection of IgG and/or IgA to BP180 NC16A to 67%, representing a 30% increase (Ali et al, 2016).…”

Section: Diagnosismentioning

confidence: 99%

Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016

Schmidt

Spindler

Eming

et al. 2017

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Considerable advances have been made in describing incidences and prevalences of these diseases and linking comorbidities with autoantibody reactivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflammatory bullous pemphigoid. Although new entities are still being described, diagnosis of most autoimmune blistering diseases can now be achieved using standardized and widely available serological test systems. Various experimental mouse models of pemphigus and pemphigoid disease are increasingly being used to understand mechanisms of central and peripheral tolerance and to evaluate more specific treatment approaches for these disorders, such as molecules that target autoreactive T and B cells and anti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus. Very recent experimental data about the immunopathology and the determinants of autoantibody formation and keratinocyte susceptibility in pemphigus were discussed. With regard to cellular mechanisms leading to the loss of cell-cell adhesion, new ideas were shared in the field of signal transduction. Major steps were taken to put the various partly contradictory and controversial findings about the effects of pemphigus autoantibodies and other inflammatory mediators into perspective and broaden our view of the complex pathophysiology of this disease. Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone as valuable medications in the treatment of bullous pemphigoid.

show abstract

“…Power et al claims that using immunohistochemistry which includes immunoperoxidase technique may increase the sensitivity of conjunctival biopsy in the diagnosis of ocular CP [143,144].…”

Section: Diagnosismentioning

confidence: 99%

Bullous Systemic Lupus Erythematosus and Cicatricial Pemphigoid

Ayvaz¹,

Gönül²,

Atay³

2018

Autoimmune Bullous Diseases

View full text Add to dashboard Cite

Bullous systemic lupus erythematosus is a rare distinctive subepidermal bullous disease seen in patients with systemic lupus erythematosus (SLE). It has characteristical clinic, pathologic, and immunologic findings including antibodies to type VII collagen, laminin 332, laminin 331, and bullous pemphigoid antigen 230. Clinical presentation combined with histopathology, immunological testing, and concomitant diagnosis of SLE according to the criteria of American College of Rheumatology, are required to distinguish bullous SLE from these bullous diseases. In patients with bullous SLE, SLE disease progression and complications may be worse. Cicatricial pemphigoid is a chronic subepidermal blistering disease which is characterized by erosive lesions of mucous membranes and skin. Pathogenesis of cicatricial pemphigoid is characterized by linear deposition of Immunoglobulin G, A, or complement 3 along the epithelial basement membrane zone. The main target antigens are bullous pemphigoid antigens 180-230, laminin 331-332, type VII collagen, and β-4 integrin subunit. Cicatricial pemphigoid may lead to serious complications such as blindness and airway obstruction. Herein, clinical, histological, immunopathological features, the diagnosis and treatment of bullous SLE and cicatricial pemphigoid diseases are mentioned to raise awareness among the dermatologists about this important but rare heterogeneous bullous disease.

show abstract

Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid

Abstract: IgG and IgA antibodies may provide a suitable diagnostic marker in MMP. Assay of salivary IgA antibodies to NC16a offers a similar diagnostic predictive value to serum.

Cited by 31 publications

References 43 publications

Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris

Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris

Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016

Bullous Systemic Lupus Erythematosus and Cicatricial Pemphigoid

Contact Info

Product

Resources

About